GLP-1/GIP weight loss therapy refers to treatment with tirzepatide, a dual receptor agonist that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in the body
Early enthusiasm was tempered due to concerns related to cost, tolerability, long-term adherence, and pharmacoequity, as well as open questions related to the long-term safety profile
Some pharmacies also reference USP for nonsterile compounding and USP for hazardous drug handling when applicable to their operations
[1,2] This has important clinical implications
Overview | Semaglutide for managing overweight and obesity | Guidance | NICE
Before you change your dosage in any way, be sure to talk with a Midi clinician or a well-trained healthcare provider to go over your options and discuss the approach that may be best for your needs